Celprogen
Develops 3D bioprinted organ models (e.g., heart, pancreas, brain) using PLA scaffolds seeded with human stem cells for regenerative medicine and drug discovery applications.
- CEO / Founder
- Jay Sharma
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $110K
- Latest Round
- Angel
Technology & Products
Key Products
3D printed scaffold human heart; 3D printed pancreas model; 3D bioprinted brain organelle; Stem cells; Cancer stem cells; Custom cell line development; Molecular diagnostics solutions
Technological Advantage
Proprietary stem cell expansion and 3D bioprinting techniques for creating complex tissue structures; all products manufactured in the USA.
Differentiation
Value Proposition
Provides functional 3D bioprinted organ models that mimic human physiology, enabling more accurate drug testing and disease modeling compared to traditional 2D cultures, potentially reducing preclinical development costs and time.
How They Differentiate
Focuses on 3D bioprinting of specific organ models (heart, pancreas, brain) using human stem cells, whereas competitors like Cellink offer broader bioprinting platforms and materials.
Market & Competition
Target Customers
Biotechnology companies, pharmaceutical firms, academic research institutions, in-vitro diagnostics labs
Industry Verticals
Biotechnology; Pharmaceutical; Medical Research; Regenerative Medicine
Competitors
Cellink; Aspect Biosystems; Precise Bio
Growth & Milestones
Growth Metrics
Over 5000 products in the market
Major Milestones
Successfully 3D printed a human heart using PLA and human cardiac stem cells (2016); Successfully 3D printed a functioning pancreas model from PLA scaffold (2016); 3D bioprinted a human brain organelle for neurological disease research